Objective: To compare oncological outcomes of patients aged 70 years treated with radical prostatectomy with those of a clinically matched younger cohort. Methods: Data from 1268 patients undergoing radical prostatectomy between 2000 and 2009 were retrospectively reviewed. Patients were classified according to age (,70 or 70 years) at the time of prostatectomy. After matching pre-operative factors (i.e. prostate specific antigen, positive biopsy cores, Gleason score, clinical stage and D'Amico risk group), 333 patients were chosen from each group. Results: The percentage of pathological stage T3 in those of age ,70 and 70 years was 30.3 and 33.0%, respectively (P ¼ 0.51). The percentage of pathological Gleason score 6, 7 and 8 was not significantly different between the two age groups (P ¼ 0.08). The percentage of organ-confined disease in those of age ,70 and 70 years was 69.4 and 67.0%, respectively (P ¼ 0.56). With a median follow-up of 50 months, 5-year prostate specific antigen recurrence-free survival in those of age ,70 and 70 years was 83.4 and 80.1%, respectively (log rank, P ¼ 0.199). Five-year cancer-specific survival in those of age ,70 and 70 years was 100 and 99.4%, respectively (log rank, P ¼ 0.317). Five-year overall survival in those of age ,70 and 70 years was 98.4 and 96.4%, respectively (log rank, P ¼ 0.228). Conclusions: Pathological and oncological outcomes in elderly patients (age 70 years) treated with radical prostatectomy were not significantly different from those of younger patients (age ,70 years). This information will help refine the indications for definitive treatment for localized prostate cancer in elderly men.
INTRODUCTION
The proportions of patients treated with radical prostatectomy (RP) aged 65 and 70 years in Japan are reported to be 63.3 and 31.4%, respectively (1) , and are much higher than those of patients in the USA or Europe (2) . The use of RP in elderly patients with localized disease could be expected to increase over the next decade, because of the aging of the general population and the expanding indications for RP in light of the introduction of robotassisted laparoscopic RP.
However, RP in elderly patients can sometimes represent a form of overtreatment and might result in undesired complications, functional impairment, decreased quality of life or excessive healthcare costs. Recent reports comparing oncological outcomes of RP versus observation raise some doubts regarding the value of RP, especially in elderly patients (3, 4) . The Prostate Cancer Intervention Versus Observation Trial (PIVOT) study showed no survival benefit for RP when compared with observation (3). In the Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4), RP was associated with a reduction in the rate of death from prostate cancer in the whole cohort, but the survival benefit was not seen in patients aged 65 years who underwent RP (4) . According to the American Urological Association 2013 guidelines, routine prostate specific antigen (PSA) screening in men aged 70 years was not recommended (5) .
On the other hand, several studies demonstrated that prostate cancer in elderly men had biologically more aggressive and locally advanced tumors, or a higher risk of biochemical recurrence and poorer survival, when compared with outcomes in younger men (6 -9) . These results support the use of RP in elderly men and argue against the use of conservative treatment.
Establishment of defined indications for RP is a necessary step to determine whether prostate cancer in elderly men has unfavorable pathological features or a higher treatment failure rate. Since most previous studies comparing pathological and oncological outcomes according to age had some degree of bias, we used a matched-pair analysis to avoid bias and to address this issue.
PATIENTS AND METHODS
This study was approved by the institutional review boards at each participating site, and institutional data-sharing agreements were established before initiation of the study. Between January 2000 and December 2009, 1268 consecutive patients with clinically localized prostate cancer underwent RP at Tohoku University, Hirosaki University, Akita University and Miyagi Cancer Center. None of the patients had a prior history of prostate surgery, nor did they undergo neoadjuvant hormonal or radiation therapy. The median number of cores obtained at the time of diagnostic biopsy was 10 (6 -24). RP was achieved in an open retropubic manner in all cases. The surgical specimen containing the prostate gland with seminal vesicles attached was serially sectioned perpendicular to the long axis of the gland. Pathological evaluation of biopsy and surgical specimens was performed at each institution by a dedicated genitourinary pathologist according to the Gleason grading system and pathological stage based on the 2002 TNM classification. Total tumor volume was measured at Tohoku University and Hirosaki University using computerassisted image analysis (NIH Image, developed and maintained by the National Institutes of Health, Bethesda, MD, USA) and was defined as the sum of the volumes of individual cancer foci (10) .
Patients were classified according to age at the time of RP (,70 or 70 years old), because the mean age of patients in this study was 68 years. Furthermore, life expectancy in 70-year-old Japanese men is estimated to be 15.11 years (11) and 70 years was considered to be reasonable as the age cutoff for the purpose of these analyses. To compare pathological and oncological outcomes between patients aged ,70 years and patients aged 70 years, a matched-pair analysis was done using the SAS macro 'gmatch' based on the greedy algorithm (12) . Matching factors were PSA, positive biopsy cores, Gleason score, clinical stage and D'Amico risk group.
Pathological findings [ pathological stage, pathological Gleason score (pGS), tumor volume, organ-confined disease (OCD), positive surgical margin (PSM), lymph node invasion (LNI)], and oncological outcomes [PSA recurrence-free survival, cancer-specific survival (CSS), overall survival (OS)] were compared between the two age groups. Insignificant cancer was defined as two cutoffs of tumor volume based on the Epstein criteria with pT2, pGS 6 and tumor volume ,0.5 ml (13) and the recent European study of screening with pT2, pGS 6 and tumor volume ,2.5 ml (14) . Pathological high-risk cancer was defined as cancer that had at least one unfavorable pathological factor, including pT3b, pGS 8, PSM or LNI (15 -17) .
The follow-up schedule after RP involved a PSA assay every 3 months for the first 2 years, every 6 months for the following 3 years, and then annually thereafter. The date of PSA recurrence was defined as the point, at which the serum PSA level exceeded 0.2 ng/ml, when RP was carried out if the PSA did not decrease below 0.2 ng/ml after surgery, or when adjuvant therapy was initiated even if PSA did not exceed 0.2 ng/ml.
Statistical analyses were performed with JMP version 9 (SAS, Inc., Cary, NC, USA) and SAS 9.2 (SAS, Inc.). Clinicopathological parameters were analyzed using the Wilcoxon rank sum test or the Fisher exact test. PSA recurrencefree survival, CSS and OS were determined by the Kaplan-Meier method. A P value , 0.05 was considered to be statistically significant.
RESULTS
Of 1268 patients treated with RP, 31.4% (398/1268) was 70 years old. Total tumor volume was measured in 54.5% (474/ 870) of those ,70 years of age and in 45.3% (179/398) of those 70 years of age.
After matching pre-operative factors, 333 patients were chosen from each group. Median age at RP in patients aged ,70 years and patients aged 70 years was 64 (45 -69) years and 72 (70 -83) years, respectively. Table 1 shows preoperative variables in the two age groups after matching. The
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On pathological findings, none of the factors, including pathological T stage, pGS, PSM, OCD, LNI and tumor volume, were significantly different between the two age groups. pGS was likely to be worse in patients aged 70 than that in patients aged ,70, but the difference did not reach the level of statistical significance (P ¼ 0.08) ( Table 2 ).
The proportion of insignificant cancer with tumor volume ,0.5 ml in patients aged ,70 years and in patients aged 70 years was 4.4 and 1.9%, respectively, (P ¼ 0.184), and the proportion of insignificant cancer with tumor volume ,2.5 ml in patients aged ,70 years and in patients aged 70 years was 4.9 and 3.1%, respectively (P ¼ 0.408). The proportion of pathological high-risk cancer with at least one unfavorable pathological factor (e.g. pGS 8, pT3b, PSM or LNI) was not significantly different among patients aged ,70 years (45.0%) when compared with patients aged 70 years (46.5%) (P ¼ 0.697) ( Table 3) .
With a median follow-up of 50 months, five-year PSA recurrence-free survival in patients aged ,70 and 70 years was 83.4 and 80.1%, respectively (log rank, P ¼ 0.199). Five-year CSS in patients aged ,70 and 70 years was 100 and 99.4%, respectively (log rank, P ¼ 0.317). Five-year OS in patients aged ,70 and 70 years was 98.4 and 96.4%, respectively (log rank, P ¼ 0.228) (Fig. 1) .
DISCUSSION
In a previous study, we recently described the pathological and oncological outcomes of elderly patients with clinically localized prostate cancer (18) . In that study, RP was more likely to be performed in those with higher-risk disease among patients aged 70 years, and those patients had significantly worse pathological outcomes than patients aged ,70 years. However, from those results, it was not clear whether or not prostate cancer in elderly patients had more unfavorable biological features than those in younger patients, since worse pathological outcomes in patients aged 70 years were mainly derived from more unfavorable pre-operative characters in patients aged 70 years when compared with patients aged ,70 years.
In the present study, pre-operative factors, including PSA, positive biopsy cores, Gleason score, clinical stage and D'Amico risk group, were completely matched among the two age groups, and pathological and oncological outcomes were not significantly different between matched-pair patients aged ,70 and 70 years. The frequency of pathologically insignificant cancer (pT2, pGS 6 and tumor volume ,0.5 ml, or pT2, pGS 6 and tumor volume ,2.5 ml) and pathologically high-risk cancer ( pT3b, pGS 8, PSM or LNI) was not also significantly different between the two age groups.
These results might help refine the indications for RP in elderly patients with localized prostate cancer. For example, if the biological features were not different according to age, it would be reasonable to increase the use of conservative treatment in elderly patients. On the other hand, in the present 
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Radical prostatectomy in elderly men study, 5-year CSS was almost 100% in the both age groups, and 5-year OS was also excellent, even in patients aged 70 years (96.4%). Life expectancy in 70 and 75-year-old Japanese men is estimated to be 15.11 and 11.57 years, respectively (11) , and that of patients who undergo RP could be much longer than general population because they are healthy enough to undergo RP. These excellent oncological outcomes in patients aged 70 years might indicate that age itself is not an important factor when considering the indication for RP, at least in patients who are in their early 70 s and are without significant co-morbidities. The reasons why our results were different from several previous studies that demonstrated unfavorable pathological or oncological outcomes in patients aged 70 years were not clear but merit discussion. Previous studies were retrospective and had significant bias between the age groups preoperatively. Kunz et al. (9) reported that patients aged 70 years had biologically more aggressive and locally advanced tumors significantly more often than those aged ,70 years but that patients aged 70 years had significantly more clinically palpable tumors, higher biopsy Gleason scores and a higher proportion of high-risk disease. Brassell et al. (8) reported that an age of 70 years was a significant predictor of biochemical recurrence after RP in multivariate analysis, although they had a statistically significant higher clinical stage, biopsy grade and PSA velocity pre-operatively. Ko et al. (19) matched patients .70 years old with younger (50-to 70-year-old) men with similar pathological features after RP to analyze the effect of age on biochemical failure and reported that patients 70 years old had an 85% higher chance of biochemical failure when compared with younger men with relatively short median follow-up time (21 months). Difference in race or region between patient populations might also account for the difference of the results, however, Kim et al. (7) analyzed the differences in clinicopathological results between two groups of Korean patients aged younger or .70 years with clinically localized prostate cancer with a retrospective and not-matched analysis and concluded patients aged 70 years had a higher possibility of locally advanced cancer than younger patients .
Although this study performed patient matching using clinical factors, several limitations deserve mention. While clinical bias between the two age groups was almost obviated by the matched-pair analysis, other pre-operative factors, such as prostate volume (20) , PSA density (21, 22) or number of biopsy cores (23) , might be associated with oncological outcomes. Moreover, some difference in the interpretation of Gleason score among genitourinary pathologists might affect the results. A median follow-up time of 50 months might be relatively short to determine the oncological outcomes of RP, and the difference in median age between the two age groups was 8 years, which might be not enough to compare the biological difference due to age. Finally, this study focused only on RP; therefore, the results cannot be generalized for other elderly patients with localized prostate cancer who selected alternative treatment. Longer follow-up, minimizing bias and expanding the age difference between the two age groups might alter the results.
We realize that age is one of the factors that should be considered when formulating indication for RP, and comprehensive assessment, including health status, comorbidities, life expectancy, oncological outcomes, function and quality of life is needed. Regardless, our results will help refine the indications for definitive treatment for localized prostate cancer in elderly men. Further study is needed to select patients who benefit from RP, especially in elderly patients, because rapid aging of society is an urgent problem.
In conclusion, pathological and oncological outcomes were not significantly different between matched-pair patients aged ,70 and 70 years. Age itself might not be an important factor for considering indications of active treatments in patients who are in their early 70s without significant comorbidities.
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